NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.
Volatility & Risk
NeuroOne Medical Technologies has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Earnings and Valuation
This table compares NeuroOne Medical Technologies and Fresenius SE & Co.”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 0.98 | -$3.61 million | ($0.95) | -1.37 |
| Fresenius SE & Co. | $25.87 billion | 1.14 | $1.43 billion | $0.79 | 16.57 |
Fresenius SE & Co. has higher revenue and earnings than NeuroOne Medical Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Fresenius SE & Co., indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares NeuroOne Medical Technologies and Fresenius SE & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
| Fresenius SE & Co. | 6.67% | 10.25% | 4.87% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for NeuroOne Medical Technologies and Fresenius SE & Co., as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
NeuroOne Medical Technologies currently has a consensus target price of $7.33, indicating a potential upside of 464.10%. Given NeuroOne Medical Technologies’ higher possible upside, equities analysts clearly believe NeuroOne Medical Technologies is more favorable than Fresenius SE & Co..
Summary
Fresenius SE & Co. beats NeuroOne Medical Technologies on 9 of the 13 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
